Multiple Sclerosis

Multiple Sclerosis – High‑Yield Study Guide for Medical Students

Definition

Multiple sclerosis (MS) is a chronic, immune-mediated demyelinating disease of the central nervous system (CNS) characterized by disseminated inflammatory lesions in time and space, affecting the brain, spinal cord, and optic nerves. It leads to variable neurological deficits separated in time, with partial recovery, and eventual accumulation of disability in many patients.

Epidemiology

MS is the most common non-traumatic cause of neurological disability in young adults.

• Age of onset: Typically 20–40 years; rare in childhood or after age 60.
• Sex: Female predominance (~2–3:1).
• Geography: Higher prevalence in temperate climates and at higher latitudes (Northern Europe, North America, Southern Australia & New Zealand).
• Ethnicity: Most prevalent in individuals of Northern European ancestry; lower but increasing recognition in other ethnic groups.
• Genetics: Increased risk in first-degree relatives; association with HLA-DRB1*15:01.
• Environmental risk factors: Low vitamin D / reduced sun exposure, smoking, adolescent obesity, prior EBV infection (especially infectious mononucleosis).

Pathophysiology

MS is driven by a complex interaction between genetic susceptibility and environmental triggers leading to an autoimmune response against CNS myelin and axons.

• Autoimmunity: Autoreactive CD4+ T cells (Th1 and Th17), CD8+ T cells, and B cells cross a disrupted blood–brain barrier and target myelin and oligodendrocytes.
• Inflammation: Perivascular inflammatory infiltrates in white matter cause demyelination, conduction block, and acute neurological deficits (relapses).
• Demyelination and remyelination: Myelin loss slows or blocks saltatory conduction; partial remyelination can occur, contributing to recovery.
• Axonal damage and neurodegeneration: Chronic inflammation leads to irreversible axonal loss, cortical demyelination, and brain/spinal cord atrophy; this underlies progressive disability.
• Lesion distribution: Characteristic lesions in periventricular white matter, juxtacortical areas, infratentorial regions (brainstem, cerebellum), optic nerves, and spinal cord.

Clinical Presentation

MS classically presents with episodes of neurological dysfunction lasting >24 hours, separated in time and affecting different CNS regions. Symptoms depend on lesion location.

Clinical Phenotypes

• Clinically isolated syndrome (CIS): First clinical episode suggestive of demyelination (e.g., optic neuritis, partial myelitis) that does not yet fulfill full diagnostic criteria for MS.
• Relapsing–remitting MS (RRMS): Clearly defined attacks (relapses) with full or partial recovery, and stable disease between relapses (most common form at onset).
• Secondary progressive MS (SPMS): Initial RRMS course followed by gradual neurological worsening with or without superimposed relapses.
• Primary progressive MS (PPMS): Progressive accumulation of disability from onset (at least 1 year), typically with later onset and less inflammatory activity.

Common Presenting Symptoms

• Optic neuritis: Subacute, unilateral painful loss of vision, decreased color vision, relative afferent pupillary defect (RAPD).
• Myelitis: Sensory level, limb weakness, paresthesia, Lhermitte sign (electric shock sensation down spine on neck flexion), bowel/bladder dysfunction.
• Brainstem/cerebellar: Diplopia (internuclear ophthalmoplegia), vertigo, ataxia, dysarthria, nystagmus.
• Cerebral/hemispheric: Motor weakness, sensory disturbances, cognitive symptoms, fatigue.

Typical Neurological Signs

• Upper motor neuron signs: Spasticity, hyperreflexia, Babinski sign.
• Sensory findings: Impaired vibration/proprioception, dysesthesia, neuropathic pain.
• Visual signs: Decreased acuity, central scotoma, RAPD, optic disc pallor post-episode.
• Cerebellar signs: Intention tremor, dysdiadochokinesia, dysmetria, gait ataxia.
• Brainstem signs: Internuclear ophthalmoplegia (INO), facial weakness, trigeminal sensory loss.

Key Symptom Patterns & Clinical Pearls

• Uhthoff phenomenon: Worsening of neurological symptoms with heat (fever, hot bath, exercise) due to impaired conduction in demyelinated fibers.
• Lhermitte sign: Electric shock sensation radiating down the spine with neck flexion, suggestive of cervical spinal cord demyelination.
• Relapse features: New or worsening neurologic symptoms lasting >24 hours, not explained by fever or infection.
• Pseudo-relapse: Temporary worsening of old deficits due to fever, infection, or heat stress; no new inflammatory activity.

Diagnosis

MS is a clinical and radiological diagnosis based on demonstrating dissemination of lesions in time (DIT) and in space (DIS) in the CNS, and excluding alternative diagnoses. The 2017 McDonald criteria are most widely used.

2017 McDonald Criteria – Core Concepts

• Dissemination in space (DIS): At least one T2 lesion in two or more typical CNS regions (periventricular, cortical/juxtacortical, infratentorial, spinal cord).
• Dissemination in time (DIT): Simultaneous presence of asymptomatic gadolinium-enhancing and non-enhancing lesions on a single MRI, or a new T2/gadolinium-enhancing lesion on follow-up MRI, or the presence of CSF-specific oligoclonal bands (OCBs) in a patient with a typical CIS.

Key Diagnostic Tools

MRI of Brain and Spinal Cord

• Preferred modality: MRI with T2/FLAIR, T1 with gadolinium contrast.
• Typical findings:
  • Multiple ovoid T2 hyperintense lesions in white matter, especially periventricular ("Dawson's fingers" radiating perpendicular to ventricles).
  • Lesions in juxtacortical, infratentorial regions (brainstem, cerebellum), optic nerves, and spinal cord.
  • Gadolinium-enhancing lesions indicate active inflammation (breakdown of blood–brain barrier).
  • Black holes (hypointense T1 lesions) correlate with severe tissue damage/axonal loss.

Cerebrospinal Fluid (CSF) Analysis

• Oligoclonal bands (OCBs): CSF-restricted IgG OCBs present in >85–90% of MS patients; support diagnosis and can substitute for DIT in 2017 criteria.
• IgG index: Elevated intrathecal IgG synthesis in many patients.
• Cell count/protein: Mild lymphocytic pleocytosis and mildly elevated protein may be seen; marked abnormalities suggest alternative diagnoses.

Evoked Potentials

• Visual evoked potentials (VEP): Prolonged P100 latency suggests optic nerve demyelination, even if clinically silent.
• Somatosensory/brainstem auditory evoked potentials: May detect subclinical lesions in sensory pathways or brainstem.

Laboratory Workup – Excluding Mimics

Important to rule out conditions that can mimic MS clinically or radiologically:

• Infections: HIV, syphilis, Lyme disease.
• Inflammatory/autoimmune: Neuromyelitis optica spectrum disorders (AQP4-IgG), MOG antibody disease, systemic lupus erythematosus, Sjögren syndrome, vasculitis, sarcoidosis.
• Metabolic/deficiency: Vitamin B12 deficiency, copper deficiency.
• Genetic/other: Leukodystrophies, CADASIL, CNS lymphoma.

Management Overview

Management of MS includes treatment of acute relapses, initiation and optimization of disease-modifying therapy (DMT), symptom control, rehabilitation, and lifestyle modification. Early treatment is associated with improved long-term outcomes.

1. Acute Relapse Treatment

• Indications: Functionally significant new neurological deficits lasting >24 hours, not explained by infection or metabolic disturbance.
• First-line: High-dose corticosteroids.
  • Adult dosing commonly: methylprednisolone 1 g IV daily for 3–5 days, with or without a short oral taper (e.g., oral prednisone 1 mg/kg for 1–2 weeks, then taper).
  • Or high-dose oral methylprednisolone regimen where appropriate (equivalent dosing).
• Mechanism: Anti-inflammatory, stabilizes blood–brain barrier, hastens recovery but does not change long-term disease course.
• Second-line for steroid-refractory severe relapse: Plasma exchange (PLEX), especially for severe optic neuritis, brainstem attacks, or transverse myelitis.

2. Disease-Modifying Therapies (DMTs)

DMTs aim to reduce relapse rate, new MRI lesion formation, and disability progression. Choice depends on disease activity, prognostic factors, comorbidities, route of administration, safety profile, and patient preference.

First-Line / Platform Therapies (examples)

• Injectables:
  • Interferon beta-1a / 1b: Immunomodulatory; reduce relapse rate and new lesions. Common AEs: flu-like symptoms, injection-site reactions, liver enzyme elevation, leukopenia.
  • Glatiramer acetate: Synthetic polypeptide that shifts T-cell profile to anti-inflammatory. Common AEs: injection-site reactions, transient chest tightness/flushing.
• Oral agents (selected):
  • Dimethyl fumarate: Anti-inflammatory and neuroprotective via Nrf2 pathway; AEs: flushing, GI symptoms, lymphopenia, rare PML with severe lymphopenia.
  • Teriflunomide: Pyrimidine synthesis inhibitor; AEs: hepatotoxicity, teratogenicity, alopecia, GI upset.
  • S1P receptor modulators (e.g., fingolimod, siponimod): Sequester lymphocytes in lymph nodes; AEs: bradycardia, macular edema, infections, liver enzyme elevation.

Higher-Efficacy / Escalation Therapies (examples)

• Monoclonal antibodies:
  • Natalizumab: Anti-α4 integrin; prevents lymphocyte migration into CNS. Highly effective; risk of PML, especially with JCV positivity, prior immunosuppression, and long duration.
  • Ocrelizumab / ofatumumab: Anti-CD20 B-cell–depleting; effective for RRMS and ocrelizumab for PPMS; AEs: infusion reactions, infections, possible malignancy signal.
  • Alemtuzumab: Anti-CD52; very potent; AEs: autoimmunity (thyroid disease, ITP), infections, infusion reactions, malignancy concerns.
• Cladribine, mitoxantrone: Less commonly used due to toxicity profiles (cardiotoxicity, leukemia risk for mitoxantrone).

Therapeutic strategies: Either start with platform therapy and escalate if breakthrough disease occurs, or start early with high-efficacy therapy in patients with aggressive disease (e.g., high lesion load, frequent disabling relapses, poor prognostic indicators).

3. Symptomatic Treatment

Symptom control significantly improves quality of life and functional status.

• Fatigue: Energy conservation, sleep optimization, treat comorbid depression; pharmacologic options include amantadine, modafinil, or methylphenidate in selected cases.
• Spasticity: Physical therapy, stretching; medications such as baclofen, tizanidine; botulinum toxin or intrathecal baclofen pump for refractory severe spasticity.
• Pain and dysesthesia: Neuropathic pain agents such as gabapentin, pregabalin, duloxetine, or tricyclic antidepressants.
• Bladder dysfunction:
  • Storage symptoms (urgency/frequency): antimuscarinics (oxybutynin, solifenacin) or beta-3 agonists (mirabegron).
  • Emptying problems: intermittent self-catheterization, alpha-blockers in selected cases.
• Bowel dysfunction: Dietary modification, fiber, stool softeners, laxatives as needed.
• Gait impairment: Physical therapy, mobility aids; dalfampridine (4-aminopyridine) can improve walking speed in some patients (contraindicated in seizure history).
• Depression/anxiety and cognitive issues: Psychological support, CBT, antidepressants; cognitive rehabilitation.

4. Rehabilitation & Lifestyle

• Multidisciplinary care: Neurology, physical and occupational therapy, speech therapy, neuropsychology, urology, and social support.
• Exercise: Regular, moderate physical activity improves fatigue, mood, and mobility.
• Smoking cessation: Smoking is associated with more rapid progression; cessation should be strongly encouraged.
• Vitamin D: Maintain adequate vitamin D levels; supplementation is often recommended if deficient.
• Vaccination: Keep immunizations up to date; live vaccines generally avoided in those on potent immunosuppressive DMTs.

Prognosis and Predictors

MS has a highly variable course. Many patients maintain independent ambulation for decades, especially with early and effective DMT. Poor prognostic features include frequent early relapses, incomplete recovery from first attacks, high lesion burden on baseline MRI, early spinal cord or brainstem involvement, and male sex with later onset.

High-Yield Clinical Pearls for Exams

• Typical patient profile: Young woman with optic neuritis or sensory/motor deficits evolving over days and partially improving, with prior episode suggestive of demyelination.
• MRI hallmark: Ovoid periventricular lesions (Dawson's fingers), juxtacortical plaques, and spinal cord lesions <2 vertebral segments in length.
• Diagnostic concept: Dissemination in time and space; CSF oligoclonal bands can substitute for DIT in 2017 McDonald criteria.
• Uhthoff phenomenon: Worsening of symptoms with heat is classic for MS although not specific.
• INO in young adult: Internuclear ophthalmoplegia in a young individual is highly suggestive of MS.
• Acute relapse treatment: High-dose IV methylprednisolone (e.g., 1 g/day for 3–5 days).
• Distinguish from neuromyelitis optica (NMO): NMO typically has longitudinally extensive transverse myelitis (≥3 vertebral segments) and severe bilateral optic neuritis; test for AQP4-IgG.
• Early DMT initiation: Associated with lower relapse rates and reduced disability progression; exam questions often emphasize early treatment.

Summary

Multiple sclerosis is a chronic, immune-mediated demyelinating disease of the CNS that typically affects young adults and presents with episodic, multifocal neurological deficits. Diagnosis relies on MRI and CSF findings that demonstrate dissemination in time and space while excluding mimics. Modern disease-modifying therapies have dramatically improved outcomes by reducing relapses and slowing disability progression, and should be combined with targeted symptomatic treatment, rehabilitation, and lifestyle optimization for comprehensive care.